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Abstract: Rho GTPases, a family of the Ras GTPase superfamily, are key regulators of the actin
cytoskeleton. They were originally thought to primarily affect cell migration and invasion; however,
recent advances in our understanding of the biology and function of Rho GTPases have demonstrated
their diverse roles within the cell, including membrane trafficking, gene transcription, migration,
invasion, adhesion, survival and growth. As these processes are critically involved in cancer initiation,
metastasis and therapeutic responses, it is not surprising that studies have demonstrated important
roles of Rho GTPases in cancer. Although the majority of data indicates an oncogenic role of Rho
GTPases, tumor suppressor functions of Rho GTPases have also been revealed, suggesting a context
and cell-type specific function for Rho GTPases in cancer. This review aims to summarize recent
progresses in our understanding of the regulation and functions of Rho GTPases, specifically in the
context of breast cancer. The potential of Rho GTPases as therapeutic targets and prognostic tools for
breast cancer patients are also discussed.
Keywords: Rho GTPases; Rho; Rac; Cdc42; breast cancer; metastasis
1. Introduction
Breast cancer is the most common form of cancer diagnosed (about 30% of all new female cancer
cases each year) and the second leading cause of cancer-related death (about 15%) in women in
the United States [1]. Furthermore, breast cancer is the most invasive type of cancer in women,
which highlights the urgent need to better understand the mechanism of breast cancer initiation and
metastasis and develop mechanism-based therapeutic strategies for this disease. Signaling networks
that function through Rho GTPases have emerged as a field that can provide exciting opportunities for
identifying new therapeutic targets and predicting better patient prognosis. Indeed, recent work has
demonstrated that breast cancer development, progression and therapeutic responses are underscored
by dysregulation of Rho GTPase-dependent signaling pathways. In this review, we focused on recent
exciting findings showing the effects of classical Rho GTPase (Rho, Rac and Cdc42) dysregulation
on breast cancer initiation and metastasis. We aimed to summarize the specific roles that these Rho
GTPases play in each step of breast cancer development and progression, as well as the outlook for
their potential to be explored as therapeutic targets and prognosis prediction factors for breast cancer.
2. Rho GTPases
Rho GTPases, a family of the Ras GTPase superfamily, consists of low molecular weight monomeric
hydrolyases that are found in all eukaryotic cells. Rho GTPases function as molecular switches by
transitioning between a GTP-bound (active or “on” state) and a GDP-bound (inactive or “off” state)
conformation (described more in depth by us and others elsewhere [2–5]). Once activated, Rho GTPases
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move to the cell membrane or other cellular compartments to interact with downstream effectors
such as protein kinases and actin-binding proteins that directly regulate the cytoskeleton as well
as influence the dynamics of both the nuclear and cell membranes [6,7]. Through these effects,
Rho GTPases regulate many cellular processes, such as membrane trafficking, gene transcription,
migration, invasion, adhesion and growth [8–10]. Although 20 Rho GTPases have been identified,
by far the most well-characterized Rho GTPases are RhoA, Rac1 and Cdc42. Each of these Rho
GTPases are central for three separate signal transduction pathways that result in the assembly of
distinct actin-based structures [11–14] (Figure 1). RhoA promotes actin–myosin contractility and
activation results in the formation and turnover of stress fibers and focal adhesions, which provide
cell–extracellular matrix (ECM) anchoring points. Rac1 activity controls the formation of membrane
ruffling and lamellipodia, seen as a large projection at the leading edge of the migrating cell. Finally,
Cdc42 signaling results in the formation of filopodia, demonstrated as actin-rich, finger-like projections
that protrude from the lamellipodia.
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3. Regulation of Rho GTPase Activities
Rho GTPases function as molecular switches that cycle between an inactive guanosine diphosphate
(GDP)-bound state and an active guanosine triphosphate (GTP)-bound state, and eukaryotic cells
employ three classes of regulators, namely, GTPase-activating proteins (GAPs), guanine nucleotide
exchange factors (GEFs) and GDP dissociation inhibitors (GDIs), to control the spatial and temporal
activity of Rho GTPases (Figure 2).
Functionally, GAPs promote the catalysis of GTP to GDP to drive GTPase inactivation,
GEFs promote the exchange of GDP for GTP which activates GTPases, and GDIs sequester GTPases in
the GDP-bound form to keep the GTPase in an inactive conformation. Due to their functions, GEFs are
generally thought to have oncogenic functions, while GAPs and GDIs are traditionally thought to have
tumor suppressive functions [5,15]. Currently, the number of GAPs and GEFs outnumber the number
of GTPases by over 3:1 for each class of regulator, demonstrating that some GAPs and GEFs target the
same Rho GTPase. However, research has shown that certain GAPs or GEFs are specific for a single Rho
GTPase over others [16–18], and this has been reviewed by us [5]. Interestingly, only about half of Rho
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GTPases are regulated by GAPs, GEFs and GDIs, which are termed classical Rho GTPases. The other
Rho GTPases, termed fast-cycling Rho GTPases, are instead regulated through their transcription and
are reviewed elsewhere [19].
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Figure 2. Regulation of Rho GTPases. (A) Newly synthesized Rho GTPases are post-translationally
modified (such as prenylation and palmitoylation) on the C-terminus to be able to interact with the
cellular or an organelle-specific membrane. (B) Once lipid modifications are added, Rho GTPases in the
guanosine diphosphate (GDP)-bound state (“off” state) can interact with guanine nucleotide exchange
factors (GEFs), which facilitate the exchange of GDP for guanosine triphosphate (GTP) and activate
the Rho GTPases, or they can also interact with GDP dissociation inhibitors (GDIs), which bind and
sequester Rho GTPases in the “off” state. This not only keeps the Rho GTPases from becoming active,
but can also protect them from degradation [17]. (C) In the GTP-bound conformation, Rho GTPases
regulate intracellular signaling cascades through binding and activating downstream effector molecules.
This signaling is terminated by the intrinsic GTPase enzymatic reaction, which catalyzes GTP to GDP,
and is enhanced by the interaction with GTPase-activating proteins (GAPs). In addition, GTP-bound
Rho GTPases can also be sent for degradation by C-terminal ubiquitination or through direct targeting
by microRNAs (D), terminating signaling. It should be noted that miRNAs bind and negatively regulate
Rho GTPase mRNA, decreasing global expression levels of Rho GTPases.
In addition to these regulators, cells also control the subcellular localization and activity of
Rho GTPases through the use of different C-terminal post-translational modifications, including
modifications by isoprenoid lipids or palmitate fatty acids, phosphorylation and ubiquitination [20–22]
(Figure 2). For example, lipid isoprenylation of the C-terminus following Rho GTPase transcription
provides a stable plasma membrane anchor [23,24]. Furthermore, Rho GTPases are not limited to a
single post-translational modification, as following isoprenylation, Rac1 can also be palmitoylated to
help stabilize Rac1 at the actin cytoskeleton [25]. However, these post-translational modifications do
not have the same effects for each Rho GTPase because isoprenylation and palmitoylation of RhoB has
been shown to induce lysosomal localization and degradation [26]. In addition to post-translational
modifications, global expression levels of Rho GTPases can be negatively regulated by microRNAs,
resulting in an overall decrease in signaling [24] (Figure 2).
Although some exceptions have been found [27,28], expression of Rho GTPases typically does not
change in breast cancer (Table 1), but instead their activity is modified. This can be due to mutations in
the Rho GTPase that result in loss of the intrinsic GTPase activity or an increased guanine nucleotide
exchange rate [29], or through expression level changes in the GAPs, GEFs or GDIs described above [30].
Nevertheless, changes in Rho GTPase activity underlies breast cancer progression [31–33]. Indeed,
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Rho GTPases have been reported to be involved in almost all steps of breast cancer initiation and
metastasis [31].
Table 1. Mutational profiles in breast cancer of the classical Rho GTPases discussed in this review.
All mutational analyses were taken from cBioPortal for invasive breast cancer (1084 total cases).
Rho GTPase Percentage (%) Mutated inInvasive Breast Cancer
Most Prominent Mutation Type
(Percentage (%) of Total Cases)
RhoA 1.38 Deletion (0.46)
RhoB 0.37 Amplification (0.18)
RhoC 0.83 Amplification (0.28)
Rac1 0.46 Amplification (0.37)
Rac2 0.37 Amplification (0.37)
Rac3 4.15 Amplification (3.69)
Cdc42 0.83 Deletion (0.37)
4. Rho GTPases in Cell Transformation, Cancer Stemness and Tumor Formation
Tumor initiation is the process by which normal cells change into malignant cells such that they
can form tumors. Spontaneous and environment-induced DNA damage and epigenetic dysregulations
likely play important roles which result in permanent changes to the molecular profile of the
cell [34–36]. Typically, upon experiencing irreparable DNA damage, cells undergo senescence
or apoptosis. However, failure to perform these mechanisms can lead to transformation, and ultimately
cancer. This is particularly important when considering breast cancer stem cells (BCSCs), which are
thought to be a major contributor to breast cancer initiation and progression due to their capability of
unlimited self-renewal and the ability to generate all cell types that comprise a tumor [36,37]. Cellular
transformation is identified using an anchorage-independent growth assay, also known as a soft agar
colony formation assay [38]. This is because the loss of a basement membrane for normal epithelial
cells to attach to is required for mRNA and protein synthesis [39]; therefore, the ability to grow without
a substrate signifies cellular transformation. Interestingly, recent research has identified an integral
role for Rho GTPases in mediating oncogenic transformation.
4.1. Rho
Controversial data exist in regard to the role that elevated Rho GTPase activity has in breast cancer
cellular transformation [40,41]. For example, Kazerounian et al. used MMTV-PyT (mouse mammary
tumor virus-polyoma virus middle T antigen) and MMTV-myc mouse models of spontaneous breast
cancer to show that loss of RhoB is critical for cellular transformation in mice, leading to the formation of
early mammary lesions [40]. Looking directly at whole-mount staining of mammary fat pads, they found
an increased number of early tumor lesions in RhoB−/− (~10 lesions per fat pad) compared with RhoB+/−
(~0.5 lesions per fat pad) mice. Furthermore, cells isolated from RhoB−/− tumor lesions displayed
enhanced anchorage-independent growth and survival compared with cells from RhoB+/− mice, which
did not grow at all. This group found similar results in MDA-MB-231 triple-negative breast cancer
(TNBC) cells, where shRNA-mediated silencing of RhoB resulted in increased anchorage-independent
growth and a malignant phenotype. It was later determined that RhoB elicits this tumor suppressive
function in cell lines by inhibiting basal phosphorylated Akt levels of all three isoforms (Akt1, 2 and 3)
through modulation of the level of epidermal growth factor receptor (EGFR) on the cell surface [40].
However, as SUM149 TNBC cells display high levels of RhoC, it is hypothesized that RhoC
contributes to cellular transformation in cell lines and partially accounts for its highly invasive
phenotype [42]. To test this, RhoC was stably expressed in normal human mammary epithelial (HME)
cells. Although stable expression of RhoC did not change cell growth, it did cause HME cells to
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form significantly more colonies under anchorage-independent growth conditions compared with
non-transfected control cells. Unexpectedly, stable expression of RhoC drove a motile and more
invasive phenotype through alterations in stress fiber and focal adhesion dynamics. More importantly,
stable expression of RhoC increased tumor formation compared with control HME cells in nude
mice [42], indicating that RhoC is sufficient for cellular transformation. Interestingly, it was found
that reversion of this oncogenic RhoC phenotype, through the use of a farnesyl transferase inhibitor,
was accompanied by a concomitant increase in RhoB [43]. This suggests that the reversion of the
oncogenic RhoC-mediated phenotype in breast cancer may be mediated by RhoB, and that RhoB and
RhoC may have antagonistic roles in TNBC cell lines. Together, these studies suggest that Rho GTPase
dysregulations may play an important role in the early stages of carcinogenesis or in cancer initiation.
The acquisition of a stem-like phenotype is thought to be a major driving force giving cells the ability
to initiate tumor formation [36,37]. This can be accomplished through EMT (epithelial-mesenchymal
transition) and can be defined by gaining the expression of stem cell markers, such as ALDH
(aldehyde dehydrogenase) [44]. In this regard, expression of RhoC was found to promote acquisition
of a stem-like state [45]. This group found that RhoC expression was positively correlated with
ALDH expression, and later identified RhoC as a potential direct regulator of ALDH expression in
breast cancer cells. To link this change in stem cell markers to a functional output, this group also
demonstrated that knockdown of RhoC reduced tumor formation [45]. Therefore, Rho GTPases can
contribute to the acquisition of a stem-like phenotype, and, since they are linked, ALDH activity could
be a readout for RhoC activity in breast cancer.
4.2. Rac
Work done by Kawazu and colleagues demonstrated key mutations in Rac proteins that promote
cellular transformation [28]. This group first isolated cDNAs for Rac1, Rac2 and Rac3 genes from various
breast cancer cell lines and performed Sanger sequencing on them. From this data, they discovered
novel Rac1 (Rac1 (P29S), and Rac1 (N92I)) and Rac2 (Rac2(P29L) and Rac2 (P29Q)) somatic mutations,
which are also detected in human tumors. To determine the transforming potential of these mutations,
this group expressed these mutant proteins in non-tumorigenic MCF10A breast epithelial cells
and evaluated anchorage-independent growth in cell culture and tumorigenicity in nude mice [28].
They found that the expression of either the Rac1 or Rac2 mutant protein resulted in enhanced
colony formation in soft agar and tumor formation and growth in mice, confirming the transforming
capabilities of Rac1 and Rac2 in breast cancer. Mechanistically, they found that these mutations resulted
in an increased rate of GDP dissociation, leading to constitutive activation of these proteins. It is
interesting to note that the fast-cycling mutations found here in cell lines (P29) occur adjacent to
man-made fast-cycling mutants (F28) [46]. This supports previous work showing that the expression of
Rho GTPases typically is not changed, but instead their activity is modified in breast cancer. However,
it should be noted that other studies have shown that some Rac1 mutations, such as those leading to
Rac1 constitutive activation, are rare in human breast tissue [47], suggesting that we should be careful
when interpreting results in cell lines.
Using an insertional mutagenesis screen followed by 3′ rapid amplification of cDNA ends
(RACE), Goka and Lippman found a different mechanism that leads to Rac1-mediated transformation
in breast cancer [48]. From this screen, HACE1 (HECT domain and ankyrin repeat-containing E3
ubiquitin protein ligase 1), an E3 ligase that tags activated Rac1 for proteosomal degradation [49],
was identified as a critical suppressor of transformation as HACE1 ablation in MCF12A cells increased
anchorage-independent growth in soft agar. Goka and Lippman further found that loss of HACE1
resulted in the accumulation of GTP-bound Rac1 and hyperactive Rac signaling, and stable expression
of HACE1 was able to attenuate anchorage-independent growth in these cells by reducing Rac1
activity [48].
Two different studies used a mutant of the Rac and Cdc42 downstream effector, p21-activated kinase
(PAK), to study the effects on cellular transformation [50,51]. The expression of a doxycycline-inducible
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PAK mutant (T423E) that behaves like normal PAK and retains its ability to bind Rac1 and Cdc42 resulted
in a significant increase in the ability of MCF-7 breast cancer cells to grow in an anchorage-independent
setting [50], and drove hyperplasia in a mouse mammary gland [51]. Looking at the biochemical
basis of the ability of this mutant to increase anchorage-independent growth, both groups found an
increase in p42/44 MAPK (mitogen-activated protein kinase) and p38 MAPK activation in T423E stably
expressing cells treated with doxycycline compared with control cells. Using specific inhibitors of
p42/44 and p38, Vadlamudi and colleagues found that MCF-7 breast cancer cells preferentially utilized
the p42/44 pathway to increase anchorage-independent growth [50]. It was also found that PAK can
regulate ER-driven transcription of target genes [51]. Together, these studies suggest that Rac and
Cdc42 drive cellular transformation by activating both of these PAK-mediated pathways.
It has been proposed that induction of cyclins, such as cyclin D1, by growth factors and oncogenes
may contribute to cellular transformation [52,53]. To determine whether this is true in breast cancer,
Lee et al. utilized an MMTV-neu mouse model to determine the contributions of Rac in Neu-mediated
induction of cyclin D1 in MCF-7 breast cancer cells [54]. Using this model, this group found that
Neu induced cyclin D1 protein levels up to 12.9-fold relative to the control. The expression of a
dominant-negative Rac1 mutant (Rac1(N17) inhibited Neu-induced cyclin D1 promoter activity by
40–50%. Furthermore, this study and others have shown that the dominant-negative Rac1(N17)
reduced anchorage-independent growth by about 50% [54,55]. All together, these data suggest that
induction of cyclin D1 and cyclin D1-induced cellular transformation involve the activation of Rac.
5. Rho GTPases in Primary Tumor Growth and Angiogenesis
5.1. Rho GTPases in Primary Tumor Growth
After transformation into a malignant cell, cells typically bypass any cell cycle checkpoints used
to suppress growth, resulting in uncontrolled growth and formation of a primary tumor. Microtubule
and actin cytoskeleton reorganization during cell division are dependent on Rho GTPases. Therefore,
not only have Rho GTPases been shown to be involved in cellular transformation, but studies have
shown that they are critically involved in cell cycle and cancer cell proliferation.
5.1.1. Rho in Cell Cycle Progression, Proliferation and Tumor Growth
Initial work demonstrated that increased Rho activity promotes cancer cell proliferation.
For example, inhibiting RhoA, B, and C activity by the bacterial protein C3 exotransferase, Liberto et al.
discovered that Rho activation is critical for EGF-dependent entry into S-phase of the cell cycle in
MCF10A cells [56]. This group found that this is in part due to RhoA-mediated activation of the cyclin
D1 promoter. Looking at this more in depth, it was found that EGF-induced DNA synthesis described
in S-phase is dependent upon Ras/ERK signaling. Furthermore, they also demonstrated that RhoA
synergizes with the Ras(V12) constitutively active mutation to promote entry into S-phase, suggesting
that RhoA activity is required for oncogenic Ras to induce cell cycle progression in cells that harbor this
mutation [56]. In support of this, Shang and colleagues demonstrated that direct inhibition of RhoA by
their drug, Rhosin, inhibited cell growth of MCF-7 breast cancer cells [57]. Lastly, transient degradation
of RhoA and RhoC proteins by targeted siRNAs significantly reduced MDA-MB-231 TNBC cell growth
in vitro and in mouse models of breast cancer [41]. All together, these data suggest that Rho inhibition
reduces cancer proliferation.
Furthermore, RhoB has been shown to positively correlate with proliferation, conflicting with
previous studies showing a tumor suppressive function of RhoB in tumor initiation [40,58]. Fritz et al.
found that RhoB (as well as RhoA and RhoC) not only has enhanced expression in breast tumors
and positively correlated with malignancy, but RhoB also positively correlated with the proliferation
index of primary tumors [59]. A more mechanistic study determined that at least in estrogen receptor
(ER)-positive breast cancer, RhoB drives proliferation by modulating the expression of the ER, leading
to changes in the cellular response to estrogen, in multiple ER-positive breast cancer cell lines [60].
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However, recent work in our lab has shown an important role for RhoA activation for inhibiting
breast cancer proliferation [61]. Using MDA-MB-231 and SUM159 TNBC cells that stably expressed
miR-200b, we were able to show that stable expression of miR-200b enhanced RhoA activation through
direct targeting of ARHGAP18, a RhoA-specific GAP. We demonstrated that increased RhoA activation
through decreased ARHGAP18 expression caused a decrease in cell proliferation compared with
control cells that have decreased RhoA activity in breast cancer.
5.1.2. Rac and Cdc42 in Cell Cycle Progression, Proliferation and Tumor Growth
Yang and colleagues found that Rac1 is an essential mediator of heregulin β1 (HRG)-induced
cell proliferation [62]. In addition to promoting cellular transformation, this group also found that
HRG-induction of cyclin D1 and p21Cip1 resulted in an increase in cell proliferation. To determine
if Rac1 was involved in this process, they next either expressed a Rac-specific GAP (β2-chimearin),
the dominant-negative Rac1(N17) mutant, or depleted Rac1 by RNAi (RNA interference). All three
methods resulted in a reduction of cyclin D1 and p21Cip1 expression levels, suggesting that Rac1 is
essential for HRG-mediated cell cycle progression and proliferation [62]. In support of this data,
this group also found that wild type β2-chimaerin, but not mutated forms of β2-chimaerin lacking
Rac-GAP activity, significantly reduces cell cycle progression through a reduction of cyclin D1 [63],
suggesting a Rac-dependent effect on cell growth. Furthermore, the Rac1(N17) dominant-negative
mutant also showed that Rac1 inhibits cell proliferation of a highly aggressive and invasive MTLn3
breast cancer cell line [55].
In addition to Rac1 described above, Rac3 has also been shown to control cell proliferation [64].
Comparing several breast cancer cell lines, Mira et al. found that the cell lines that grew the most under
low serum conditions displayed more active Rac3 than slowly growing cells. Consistent with this cell
line data, hyperactive Rac3 was also found in human metastatic breast cancer tissues. The expression
of a constitutively active Rac3 mutant (Rac3(V12)) in HMEC184 normal mammary epithelial cells,
which endogenously express low levels of active Rac3, caused increased proliferation as assessed by a
BrdU (Bromodeoxyuridine) incorporation assay. Mechanistically, it was found that Rac3 promotes cell
proliferation through the p21-activating kinase (PAK)-JNK (c-Jun N-terminal kinase) cascade [64].
Research has also shown that Cdc42 is integral for EGF (epidermal growth factor)-mediated
cell proliferation in breast cancer [65]. Comparing MDA-MB-231 and BT20 TNBC cells with MCF-7
estrogen-positive (ER+) breast cancer cells, Hirsch et al. found that the TNBC cells expressed > 3-fold
higher levels of activated Cdc42 compared with MCF-7 cells, and this increase positively correlated
with expression levels of EGFR. Although silencing of Cdc42 through RNAi resulted in inhibition of
TNBC cell proliferation, they found no change in the DNA content in cells, which suggests that the
effects on proliferation were due to inactivation of Cdc42. Interestingly, this group found that silencing
Cdc42 significantly reduced levels of EGFR on the surface of cells, and that expression of a c-Cbl-N480
mutant, which does not associate with active Cdc42 but still binds and ubiquitinates EGFR, blocks
Cdc42-induced proliferation [65]. These data together suggest that Cdc42 is critical for EGF-induced
breast cancer cell proliferation.
5.2. Rho GTPases in Angiogenesis
As tumors grow, the cells at the center of the tumor are subjected to hypoxic conditions [66].
Therefore, for metastatic spread to occur, growth and integration of the vascular network are important.
Tumors overcome this hypoxic barrier by hijacking their surrounding cells to initiate angiogenesis.
This allows new blood vessels to form within the tumor, alleviates nutrient deficiency and promotes
metastasis. As Rho GTPases function within specific vascular cell types, and some Rho GTPases are
also expressed in diseased vessels [67], recent studies have shown that Rho GTPases are important
for angiogenesis.
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5.2.1. Rho
In addition to promoting cellular transformation and tumor formation described above,
Kazerounian and colleagues found that RhoB also contributes to angiogenesis [40]. Analyzing
human tumor and normal tissues, they found that RhoB is highly expressed in the tumor-associated
blood vessels compared with blood vessels of adjacent normal tissue, suggesting that RhoB is important
for tumor vasculature. This data was further confirmed in their mouse model where tumors from
RhoB-/- mice displayed less CD31, an endothelial cell marker, and displayed a general defect in
angiogenic sprouting.
Two separate studies from the same group have shown that RhoC regulates angiogenesis in an
inflammatory and TNBC cell line [68,69]. An ELISA analysis on cell-conditioned media from HME
cells with and without stable expression of RhoC demonstrated that cells that stably express RhoC
produce significantly more angiogenic factors compared with cells that do not stably express RhoC.
More specifically, this group found that RhoC-expressing cells made around 10-fold more vascular
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), as well as about 5-fold
more interleukin-6 (IL-6) and interleukin-8 (IL-8). HME cells stably expressing RhoC also produced
these angiogenic factors at levels comparable to parental SUM149 TNBC cells, which express high levels
of endogenous RhoC. To test the functionality of the angiogenic factors, van Golen et al. used a rat aortic
ring assay, which showed that expression of RhoC promoted microvessel outgrowth. The inhibition of
RhoA/B/C by C3 exotransferase reduced the production of VEGF, bFGF, IL-6 and IL-8, suggesting that
production of these angiogenic factors was Rho-dependent.
5.2.2. Rac and Cdc42
To determine the effects of Rac1 and Cdc42 on angiogenesis, Ma and colleagues incubated human
umbilical vein endothelial cells (HUVECs) with conditioned media from MCF-7 cells that stably
expressed either the Rac1(V12) or Cdc42(L61) constitutively active mutant [70]. They found that the
conditioned media from either constitutively active mutant induced the formation of significantly
more capillary tubes, which is a precursor to and surrogate for blood vessel formation, compared with
the control. Targeted RNAi experiments showed that inhibition of Rac1 and Cdc42 resulted in the
concomitant reduction of VEGF, and overexpression of either the Rac1(V12) or Cdc42(L61) mutant
drove an increase in VEGF expression. Interestingly, it was later determined that p53 was responsible
for mediating this Rac1- and Cdc42-mediated induction of VEGF [70].
Using a Rac-specific inhibitor, another study has also identified a critical role for Rac in angiogenesis.
As they had previously found that mammary tumors treated with their Rac-specific inhibitor (EHop-016,
which inhibits Rac activity through inhibiting the oncogenic GEF Vav [71]) showed an 85% decrease
in surface blood vessels compared with vehicle-treated tumors [72], Castillo-Picardo and colleagues
wanted to determine if EHop-016 inhibited angiogenesis. To this extent, treating HUVECs with
EHop-016, they found that the inhibitor inhibited capillary tube formation in vitro. Together, these data
suggest that Rac and Cdc42 activity is important for angiogenesis in breast cancer.
6. Rho GTPases in Breast Cancer Metastasis
Metastasis is a complex, multi-step process by which a cancer cell moves away from the primary
tumor, resulting in the development of a secondary (termed metastatic) tumor at a distant organ
separate from the primary site of cancer. As metastasis is a highly inefficient process [73], the cells
that accomplish this have likely undergone extensive genetic and epigenetic changes that benefit the
survival, growth, migration and invasive capabilities of the cell. In general, metastasis is broken down
into six major steps [74,75]: (1) primary tumor growth and angiogenesis, (2) nearby tissue invasion
and migration away from the primary tumor, (3) intravasation into the blood and lymphatic systems,
(4) survival and circularization within these systems, (5) extravasation out of the blood and lymphatic
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systems and (6) outgrowth and colonization of the secondary site. Each one of these steps represents
an important barrier that tumor cells must overcome in order to successfully metastasize.
The current knowledgebase of research into Rho GTPases demonstrates that they can affect each
step of the metastatic cascade. Therefore, this section will summarize this work with respect to the six
major steps described above.
6.1. Rho GTPases in Migration and Invasion
A critical property that cells must acquire in order to successfully metastasize is the ability to
move away from the primary tumor site. Cells migrate in vitro and in vivo as either single cells or
as a collective (sheets or groups) [76], which is driven by the dynamic formation and disassembly of
actin-based structures. Rho GTPases are critical regulators of the actin cytoskeleton, and thus have
been shown to be critical mediators of cancer cell migration and invasion [77].
6.1.1. Rho
Studies with RhoA have demonstrated controversial effects on breast cancer cell migration.
Shang and colleagues developed an inhibitor that specifically binds RhoA and inhibits GEF-mediated
activation [57]. Using this inhibitor, this group found that inhibition of RhoA significantly decreased
MCF-7 cell migration and invasion as determined by a transwell assay. In a separate study utilizing a
FRET (Fluorescence resonance energy transfer) reporter that can allow for real-time quantification of
RhoA, enhanced RhoA activity was found in the invasive PyMT-induced breast tumors relative to
control tumors [78]. Similarly, two further studies demonstrated that silencing RhoA by RNAi reduced
the migration and invasion of MDA-MB-231 [41] and SUM149 [79] TNBC cells.
However, we and others have demonstrated that in MDA-MB-231 and BT20 cells, inhibition
of RhoA actually promotes migration and invasion, ultimately leading to successful metastasis.
In addition to inhibiting proliferation described above, enhanced activation of RhoA by stable
expression of miR-200b also resulted in decreased migration as assayed in a wound healing assay [61].
The re-expression of ARHGAP18, a RhoA-specific GAP, was able to overcome the inhibitory effects of
RhoA activation on migration. In support of this data, Kalpana et al. demonstrated that knockdown
of RhoA increased Matrigel invasion in two TNBC cell lines and 4T1 mouse mammary cells [80].
Furthermore, the expression of a dominant-negative RhoA(T19N) promoted, and the constitutively
active RhoA(Q63L) decreased, 4T1 cell invasion. Lastly, this group demonstrated that RhoA expression
was sufficient to inhibit 4T1 invasion into the sentinel lymph nodes of BALB/c mice partially through
modulating CCL5-CCR5 and CXCL12-CXCR4 chemokine signaling. All together, these studies suggest
contradicting effects, and may point to a more context-dependent role for RhoA on breast cancer
motility and invasion.
Similar to RhoA, RhoB effects on breast cancer migration and invasion are complex.
In MDA-MB-231 TNBC cells, Ju et al. found a decrease in migratory velocity, persistence and
displacement of cells that stably expressed RhoB or complete RhoB knockout cells in a 3D collagen
matrix [81]. A decrease or increase of RhoB also significantly reduced spheroid invasion compared
with wild-type (WT) control spheroids under hypoxia conditions. However, in contrast to migration
and invasion, they found that reduced RhoB did not affect invasion into lymph nodes, whereas RhoB
stable expression did reduce lymph node invasion [81]. These data suggest that either increased or
decreased RhoB expression has significant effects on breast cancer migration and invasion.
In contrast to RhoA and RhoB, research is more conclusive on the enhancing effects of RhoC on
breast cancer migration and invasion. High levels of endogenous RhoC found in SUM149 TNBC cells
or stable expression of RhoC in HME cells resulted in enhanced cell migration and invasion, and these
oncogenic effects of RhoA/B/C were abrogated by treatment with the C3 exoenzyme Rho inhibitor [69].
Another study found that Akt1 (Protein kinase B) is likely responsible for the enhanced migration in
SUM149 TNBC cells because it directly phosphorylates RhoC [82]. In further support of the oncogenic
effect of RhoC, siRNA silencing of RhoC decreased breast cancer migration and invasion [41,79,83].
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6.1.2. Rac and Cdc42
Feng and colleagues found that Rac1 activation is critical for RASAL2 (RAS protein activator like
2)-mediated TNBC invasion [84]. This group profiled global miRNA expression in the aggressive
MDA-MB-231 and BT549 TNBC cell lines. They found that miR-203 was significantly decreased
in these cell lines, and further analysis confirmed that RASAL2, a Ras GAP, was a direct target of
miR-203. In contrast to its role in luminal ER-positive breast cancer, patient data analysis showed
that RASAL2 expression correlated with worse prognosis in TNBC. It was demonstrated that the
oncogenic activity of RASAL2 was mediated by Rac1 activation, and that Rac1 activation promoted
invasion [84]. Mechanistically, it was determined that Rac1 activation was increased in these cells
because RASAL2 antagonizes the Rho GAP, ARHGAP24, suggesting a higher complexity to Rho
GTPase activity regulation by GAPs, GEFs and GDIs.
Many studies have used or identified new Rac inhibitors to study the mechanistic effects of
Rac inhibition on migration and invasion. To this extent, Katz et al. found that Rac1 and Rac1b,
a constitutively active mutant Rac1 isoform that only differs by 19 amino acids in frame insertion,
are highly expressed and active in primary breast cancers cultured for a long period of time in a
collagen-based matrix [85]. The treatment of these explants with EHT1864, a pan-Rac inhibitor, blocked
invasion into the surrounding collagen of the culture system. It was found that this was accomplished
through a Rac1-STAT3-dependent mechanism. ZINC69391 was also identified as an inhibitor for Rac1
as it blocks the ability of Rac1 to interact with GEFs [86]. Further investigation with the inhibitor showed
that preventing Rac1 activation by ZINC69391 reduced EGF-induced actin reorganization and reduced
cell migration as assayed by wound healing in MDA-MB-231 and F3II breast cancer cells. De and
colleagues used NSC23766 and W56, other Rac1 inhibitors, in various TNBC cells to demonstrate
that Rac1 activation was necessary for Wnt3A (Wnt family member 3A)- and fibronectin-stimulated
migration and invasion [87]. Lastly, Humphries-Bickley et al. synthesized a Rac/Cdc42 dual inhibitor,
MBQ-127, which targets the shared downstream effector (p21-activated kinase (PAK), Figure 1) and is
a much more potent inhibitor than other specific inhibitors (such as EHop-016) [88]. The inhibition
of Rac and Cdc42 by MBQ-127 resulted in a significant reduction in migration as well as invasion.
All together, these data show that enhanced Rac1 activation promotes breast cancer migration and
invasion. However, studies have shown that some of these Rac inhibitors, in particular NSC23766
and EHT1864, have some critical Rac-independent effects on normal cells in mice at concentrations
similar to those used in cancer studies [89]. Therefore, data from studies using these inhibitors should
be analyzed cautiously.
Research in our lab utilizing microRNAs supports the oncogenic effect of Rac1 on breast cancer
cell migration. We found that stable expression of either miR-200b [90] or miR-205 [91] in two TNBC
cell lines, MDA-MB-231 and SUM159, significantly reduced Rac1 activation. We later determined that
this reduction of Rac1 activation resulted in a concurrent decrease in cell migration compared with
control cells as defined by a wound healing and transwell cell migration assay. We also found that
miR-205 expression inhibited invasion through Matrigel [91], further confirming the oncogenic role of
Rac1 in breast cancer cell migration and invasion.
In support of Rac1 function in breast cancer, studies have also shown that Rac3 activation promotes
invasion. Work specifically with invadopodia, actin-rich protrusions that help degrade the ECM [92],
have demonstrated that Rac3 activation is critical for their formation and maturation, and that Rac3
activation at invadopodia is mediated by Vav2 and βPIX (ARHGEF7) Rho GEFs in TNBC cells [93,94].
However, Rac3-mediated invasion may be specific for TNBC as reduction of Rac3 in MCF-7 cells, a less
aggressive and luminal breast cancer cell line, did not have any significant effects on parameters of
aggressiveness [95].
Research has shown that Cdc42 activation promotes breast cancer cell migration. As disruption
of epithelial architecture is a hallmark of breast cancer, Bray and colleagues developed a
TetO-Cdc42-overexpressing mouse model to study the effects of Cdc42 on epithelial structure [96].
Using this model, this group found that the expression of Cdc42 drove increased mammary gland
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branching. Isolating epithelial cells from the mammary gland, Cdc42-overexpressing mammary gland
cells were found to migrate and invade significantly more than matched control cells, and this was
accompanied by an increase in MAPK signaling. In support of this, it was also found that Cdc42
activation promoted the ability of breast cancer cells to close a wound and migrate in a Boyden
chamber [65]. However, the expression of wild-type Cdc42 was found to have no significant effect on
the ability of cancer cells to migrate across collagen [97], suggesting context and substrate specificity
for Cdc42 effects on motility. Altogether, these data demonstrate the pro-migratory effects of Rac and
Cdc42 activation in breast cancer cells.
6.2. Rho GTPases in Intravasation and Survival in Circulation
To successfully metastasize, a cell must enter the circulation, a process termed intravasation,
and survive. Cells that successfully enter the circulation are termed circulating tumor cells (CTCs).
Not only are the properties of the vasculature, including vessel density and diameter, important for
intravasation, but also gene expression changes within the cell greatly attribute to a cell infiltrating into
the blood and lymphatic systems. For example, Notch signaling [98], tumor-associated macrophages
(TAMs) [99] and transforming growth factor β (TGFβ) signaling [100] have been shown to enhance
intravasation. Additionally, new blood vessels formed in the primary tumor through angiogenesis are
leaky and can also facilitate angiogenesis [101,102]. Limited information exists about the role of Rho
GTPases in intravasation, but the work done suggests that Rho GTPase activity promotes intravasation
and survival in circulation. Reymond and colleagues identified Cdc42 as a critical regulator of breast
cancer cell intravasation, as RNAi targeting of Cdc42 significantly inhibited the ability of MDA-MB-231
cells to migrate and invade through a layer of endothelial cells [103]. Additionally, dominant-negative
mutants of RhoA (RhoA(N19)), Rac1 (Rac1(N17)) and Cdc42 (Cdc42(N17)) each significantly reduced
the number of cells that were found in the blood stream after a subcutaneous injection of MTLn3 breast
cancer cells into nude mice compared with wild-type Rho GTPases [55], suggesting that Rho GTPases
are not only critical for intravasation, but also for survival in circulation.
Along these lines, once cells have successfully intravasated into circulation they need to adapt to
a harsh environment to survive. To facilitate survival, CTCs often reprogram certain cellular processes
such as apoptosis and anoikis to survive. In this regard, the expression of geranylgeranylated RhoB,
one of the major prenyl modifications critical for Rho GTPase function, was found to promote apoptosis
of breast cancer cells [104]. In contrast, loss of Rac1 activation through an inhibitor (NSC23766) induced
apoptosis, and the expression of a dominant-active Rac1 mutant (Rac1(V12)) was able to rescue the
effects of the inhibitor [105]. Therefore, more research is needed to identify the effects of specific Rho
GTPases in breast cancer apoptosis.
6.3. Rho GTPases in Extravasation and Metastatic Colonization
The final steps in the metastatic cascade require cancer cells to arrest in circulation, extravasate
from the circulation and proliferate to colonize a distant organ. The number of CTCs far exceeds the
number of metastatic foci that develop [106], suggesting a highly inefficient process. However, cells
can alter cytoskeletal components to enhance migration and invasion to the distant organ and increase
the efficiency of metastasis [107]. Therefore, Rho GTPase activity is important for effective colonization
by breast cancer cells.
6.3.1. RhoA
In support of actin cytoskeleton rearrangements important for metastasis, studies have found that
activation of RhoA is critical for colonization [55,108]. Utilizing tail vein injection, the knockdown
of RhoA, either through RNAi or expression of a dominant-negative mutant, reduced or blocked
MDA-MB-231 metastatic lung colonization, respectively. However, recently it was found that RhoA
knockdown had no significant effect on metastatic lung colonization of breast cancer cells in a syngeneic
mouse model of breast cancer [80]. Discrepancies between the outcomes of these studies may arise
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from the different cells used in the assay or the method used to reduce RhoA activation, or due to the
difference in time points at which the measurements were taken. Nonetheless, more research is needed
to discern the function of RhoA activity on metastatic colonization.
6.3.2. Rac1 and Cdc42
In addition to reducing migration and invasion as described above, the Rac1-specific inhibitor
ZINC69391 also inhibited lung colonization in a syngeneic animal model [86]. To specifically
measure extravasation and metastatic colonization, F3II breast cancer cells were injected into
the tail vein of BALB/c mice. This group found that daily treatment of mice with ZINC69391
significantly reduced the formation and size of metastatic lung colonies. In support of this,
the expression of the dominant-negative Rac1 mutant (Rac1(N17)) also completely blocked metastatic
lung colonization [55]. Similar to studies with Rac1, inhibition of Cdc42 activation by RNAi or
expression of a dominant-negative mutant reduced the ability of breast cancer cells to form lung
metastatic foci [55,103]. Altogether, this data suggests that the activation of Rac1 and Cdc42 is critical for
breast cancer extravasation and metastatic colonization, and that ZINC69391 may provide a promising
therapeutic option for aggressive breast cancer.
7. Rho GTPases in Breast Cancer Therapy Resistance
One of the most challenging barriers to successfully treating cancer is the development of
chemoresistance or radioresistance. Developing either of these resistances not only promotes metastasis,
but they are also thought to be primary causes of disease recurrence. Mechanisms that contribute
to these resistances include, but are not limited to, (1) inadequate delivery of the chemotherapeutic,
(2) undergoing epithelial-to-mesenchymal transition (EMT, a developmental program where an
epithelial cell acquires mesenchymal-like characteristics such as increased migration and invasion) and
(3) activation of oncogenic and inhibition of tumor suppressive signaling pathways [109–112]. Focusing
on cellular reprogramming, cells effectively evade drugs by altering genes involved in resistance, and as
such studies have shown that altering Rho GTPase activation plays a role in both chemoresistance
and radioresistance. One of the major mechanisms underlying chemoresistance is acquisition of a
stem-like phenotype, and the effects of Rho GTPases on the acquisition of a stem-like phenotype is
discussed above. Therefore, this section will discuss the effects of Rho GTPases on chemoresistance
and radioresistance.
In support of RhoC as a mediator of chemoresistance, Kawata and colleagues separately found
that RhoC protein expression was significantly higher in breast tumor tissue after chemotherapy
compared with tumor tissue taken before therapy [113]. To discern whether RhoC is important
for response to therapy, they tested whether this also happened in culture. Indeed, treatment of
MCF-7 breast cancer cells with the chemotherapeutic, etoposide, resulted in increased RhoC expression,
and stable expression of a constitutively active RhoC resulted in the induction of an EMT-like phenotype
characterized by a reduction of membrane-expressed E-cadherin. As described above, RhoC expression
is positively correlated with the expression of ALDH, a breast cancer stem cell marker, and is a potential
direct regulator of ALDH expression in breast cancer cells [45]. Since ALDH has been shown to confer
cellular resistance to a variety of cytotoxic drugs used for breast cancer, such as cyclophosphamide
and its active derivative [114,115], doxorubicin [116] and cisplatin [116,117], this offers a potential
mechanism for how RhoC mediates chemoresistance in breast cancer cells.
Zhao and colleagues found that Rac1 is highly activated in trastuzumab-resistant SKBR3 breast
cancer cells [118]. To confirm whether Rac1 plays an important role in trastuzumab-resistant cells,
this group inhibited Rac1 activity using NSC23766 and then tested the sensitivity to trastuzumab.
While trastuzumab or NSC23766 alone decreased cell viability, combined treatment decreased cell
viability significantly more than either of the treatments alone. To further confirm the role of Rac1 in
trastuzumab resistance, they treated cells with an siRNA directed against Tiam1, a Rac1 GEF, and found
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results similar to that of NSC23766 treatment on cell viability [118]. Together, these results demonstrate
that Rac1 activation plays a critical role in regulating trastuzumab resistance in breast cancer.
In addition to chemotherapy, patients are often treated with small doses of targeted ionizing
radiation (IR), also known as radiotherapy, to kill breast cancer cells. Two separate studies demonstrated
that subjecting breast cancer cells to IR resulted in the immediate increase of Rac1 [119,120]. To confirm
the role of Rac1 in radioresistance, they found that inhibition of Rac1 using a specific inhibitor
(NSC23766), a dominant-negative Rac1(N17) mutant, or RNAi drove cell death in response to IR,
suggesting that a decrease in Rac1 may help sensitize cells to radiotherapy.
8. Use of Rho GTPases as a Prognostic Tool for Breast Cancer
Rho GTPases have been shown to be difficult to develop drugs against due to their structure, their
affinity for GTP and GDP and the high concentration of GTP inside cells (described elsewhere [121–123]).
In addition to their structure, the fact that Rho GTPases are critically involved in numerous processes
also adds an additional layer of complexity to successfully targeting Rho GTPases in cancer [121,124].
Therefore, it is a more reasonable approach to target the activators of Rho GTPases [15,123]. Alternatively,
a potential effective clinic use for Rho GTPases is as prognostic biomarkers. This is because identifying
biomarkers that can serve as an early detection method or as a predictive tool is essential for better
patient prognosis. Research on the efficacy of using Rho GTPases as prognostic tools in breast cancer
is somewhat limited, where current prognostic studies focus either on the expression levels of Rho
GTPase regulators (GAPs, GEFs or GDIs) or have found expression changes in the Rho GTPases
themselves. Overall, the literature suggests that Rho GTPase expression and activity are positively
associated with breast tumor progression and metastasis.
Studies have shown the potential of Rho GTPases themselves in patient prognosis. A study by
Fritz et al. found that the protein expression of Rho, but not Rac or Cdc42, varied across histological
tumor grade [27]. Specifically, grade I tumors displayed low protein expression of RhoA, B and C,
whereas their expression was increased in grade III tumors. Rho GTPase protein expression also
positively correlated with the expression of Ki-67, a marker of proliferation, in human breast samples.
Interestingly, this correlation was not found with Rho GTPase mRNA, suggesting that the change in
expression is not regulated on the mRNA level. In support of this, RhoC protein was found to be
exclusively expressed in invasive breast carcinomas and not in normal breast, atypical intraductal
hyperplasia or ductal carcinoma in situ, and increased levels of RhoC protein positively correlated with
node-positive tumors [125–127]. The Rac1b isoform was also found to be increased in breast tumors
compared with the surround stroma, and MMP3, a known upstream activator of Rac1b, was found to
positively correlate with distant metastasis-free (DMFS) and higher grade luminal and basal subtypes
of breast cancer [128].
In terms of Rho GTPase regulators, Aleskandarany and colleagues found that the expression of
ARHGAP18, a RhoA-specific GAP, is associated with improved prognosis for patients with breast
cancer [129]. Interestingly, they found that if ARHGAP18 was expressed in both the cytoplasm and
nucleus, it was associated with improved prognosis. However, if ARHGAP18 was only expressed in
either the nucleus or cytoplasm, it was positively correlated with lymphovascular invasion and higher
grade, respectively, in breast cancer [129]. This suggests that cellular localization is an important factor
that needs to be taken into account with Rho GTPase regulators and patient prognosis. In addition to
finding the correlation of enhanced RhoC protein levels with node-positive breast tumors, Jiang et al.
also found that expression levels of RhoGDI
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and metastasis 1), were found in breast tumors compared with normal background breast tissue,
and positively correlated with a poor prognostic index [130]. More specifically, they also found that
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the level of TIAM-1 was significantly higher in tumor tissue from patients who died from breast cancer
compared with those who survived. The finding that these GEFs are found differentially expressed
between breast cancer and normal tissues supports other studies that also found expression changes of
other Rho GTPase regulators in breast cancer [30,131–133]. Together, these data suggest that increased
protein expression of certain Rho GTPases and Rho GTPase activators is correlated with worse patient
prognosis, and that Rho GTPases may be promising prognostic tools in the clinic. However, due to the
complexity of Rho GTPase regulation and the controversial function of Rho GTPases in breast cancer,
more research is needed to look into the role of Rho GTPases as a prognostic marker or biomarker.
9. Conclusions and Future Perspectives
Studies on Rho GTPases in breast cancer have greatly enhanced our knowledge about the critical
roles they play in breast cancer development and metastasis. Although contradicting data do exist,
the literature generally supports the notion that Rho GTPase activation drives breast cancer progression
by affecting each step of the metastatic cascade (Figure 3).
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lead to the oncogenic function demonstrated in their studies. This is also exacerbated by the fact that 
current studies with Rho GTPases utilize methods that result in expression changes of the Rho 
GTPase, but expression changes of Rho GTPases are not typically found in human tumors and cancer 
tissues. In any case, more research is needed to support or refute this hypothesis. 
In addition to understanding the context-dependent roles of Rho GTPases in breast cancer 
initiation and progression, the identification of localization-specific effects of Rho GTPase regulators 
ff i iti ti t t i
st ies have shown conflicting data (specifi ally in the case of Rho), t e literatur generally agrees
that incre sed activation of Rh GTPases results in breas ca cer ini iation, metastatic progre sion,
chemoresistanc and radioresistance.
t re researc ill el t etter i e tif t e ec a is s erl i ase effects
reast ca cer i itiati , t era resista ce a etastasis. ue t t eir ell- effects t e
acti c t s elet , c f t e r s rr i ases f c ses t e effects i rati
a i asi . o ever, the t er ste s f t e etastatic casca e are erst ie , a t eref re,
st ies to determine the effects of Rho GTPases on these steps and processes are needed. Furthermore,
research will need to better identify the context in which each Rho GTPase acts as an oncogene or tumor
suppressor in breast cancer. This is particularly necessary for RhoA, where data support both oncogenic
and tumor suppressive roles in breast cancer progressio . Since studies have identified loss-of-function
RhoA mutations in other types of cancers [134–138], we argue that evidence supports that wild-type
RhoA functions as a tumor su press r. As the inhibition of RhoA in the met ods described above
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does not discriminate between wild-type and mutant forms, this may lead to the oncogenic function
demonstrated in their studies. This is also exacerbated by the fact that current studies with Rho
GTPases utilize methods that result in expression changes of the Rho GTPase, but expression changes
of Rho GTPases are not typically found in human tumors and cancer tissues. In any case, more research
is needed to support or refute this hypothesis.
In addition to understanding the context-dependent roles of Rho GTPases in breast cancer
initiation and progression, the identification of localization-specific effects of Rho GTPase regulators
warrants further investigation. This work found that either nuclear or cytoplasmic localization of
a Rho GAP promoted cancer progression, while expression of this GAP in both the nucleus and
cytoplasm correlated with better patient prognosis [129]. As nuclear localization and cytoplasmic
localization have been reported for other Rho GAPs [139,140], this may be a common mechanism for
regulating Rho GTPase activation in breast and other cancers. While this will help in our understanding
of localization-dependent regulation of Rho GTPase activity, it may also offer a prognostic tool for
predicting the prognosis of breast cancer.
Lastly, the vast majority of the work on Rho GTPases on breast cancer initiation and progression
focuses on the three most prominent members, RhoA, Rac1 and Cdc42. Future work will need to
address the effects of other classical and non-classical Rho GTPases, as these Rho GTPases may also
offer attractive targets and therapeutic options for breast cancer. Overall, Rho GTPases in breast cancer
provide new challenges and opportunities for the development of new general and personalized
therapeutic strategies for breast cancer.
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